BRKR · Bruker
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $56
Note written ·
How this view changed
- · Rating raised from Low to Medium. Results, 4 November 2026: Bruker's Q3 2026 adjusted EPS of $0.56 beat the $0.42 estimate, adjusted operating margin rose to 16.3% from 12.3%, and organic revenue was positive at 0.7%, with organic guidance of 1%-2% and adjusted EPS guidance of $2.10-$2.15 reaffirmed.
Price against the kill line
10.0% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $56.00, on record since 11 November 2026. The shares are up 6.9% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $56, which would erase the advance that followed the 4 November 2026 third-quarter report; a fourth-quarter organic revenue decline or a new goodwill impairment would also break the case.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 874
- Revenue, change on a year (%)
- +1.6
- Gross margin (%)
- 49.1
- Operating margin (%)
- −10.4
- Free cash flow, four quarters ($M)
- 245
- Net cash, cash less debt ($M)
- −1,594
- Enterprise value to sales (×)
- 3.1
- Free-cash-flow yield (%)
- 2.6
All filed numbers
What Bruker reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 874 | +1.6 | 49.1 | −10.4 |
| first filed | 839 | +5.2 | 49.6 | −7.8 |
| first filed | 823 | +2.7 | 46.1 | 1.2 |
| first filed | 977 | −0.2 | 46.0 | 7.8 |
| first filed | 861 | −0.5 | 44.1 | −6.0 |
| first filed | 797 | −0.4 | 44.9 | 1.5 |
| Pre-tax income ($M) | −120 |
| Net income ($M) four quarters: −123 | −112 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +0.5 |
| Operating cash flow ($M) | 342 |
| Capital spending ($M) | 97.1 |
| Free cash flow ($M) | 245 |
| Cash and short-term investments ($M) | 120 |
| Debt ($M) long-term debt | 1,713 |
| Net cash, cash less debt ($M) | −1,594 |
| Deferred revenue ($M) −3.2% on a year | 544 |
| Backlog, orders not yet delivered ($M) +33.5% on a year | 2,776 |
| Receivables ($M) | 564 |
| Inventory ($M) | 1,103 |
| Shareholders' equity ($M) including non-controlling interests | 2,306 |
| Market value ($M) | 9,393 |
| Enterprise value, market value plus net debt ($M) | 10,986 |
| Enterprise value to sales (×) | 3.1 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 4.1 |
| Free-cash-flow yield (%) | 2.6 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 8.3% of shares outstanding sold short, 5.7 days of average trading to cover, +2.1% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $106K |
| 12 monthsfrom | $0 | $3.4M |
The thesis
Bruker Corporation's third-quarter report on 4 November 2026 improved the earnings case but not the sales case: adjusted operating margin jumped and cash flow turned positive, while organic revenue grew only 0.7% and reported sales guidance was cut again. The fourth-quarter report in early February 2027, with the first 2027 guidance, settles whether organic growth accelerates as management says it will.
Bruker reported revenue of $874.0 million, up 1.6% reported and 0.7% organic, against a $868.8 million analyst estimate (company news, 4 November 2026). Adjusted earnings per share (EPS) were $0.56 against a $0.42 estimate. Adjusted operating margin was 16.3%, up from 12.3% a year earlier. Free cash flow was $96.7 million, against negative $54.1 million a year earlier.
Bruker lowered full-year 2026 revenue guidance to $3.520–$3.560 billion from $3.540–$3.570 billion and affirmed adjusted EPS of $2.10–$2.15 (company news, 4 November 2026). Per the report coverage, the cut reflects currency, and organic growth guidance of 1% to 2% was reconfirmed. Management expects lower-mid-single-digit organic growth in the fourth quarter (MarketBeat call summary, 4 November 2026).
The story is well known: the recovery story has been well known since the 4 August 2026 second-quarter report, and the 4 November 2026 results moved the debate from guidance to whether margin gains and bookings turn into sales. The adjusted close on 10 November 2026 was $62.24, 6.5% below the 52-week high of $66.54.
Bullish and bearish views on Bruker Corporation
The bull case on Bruker Corporation (BRKR), in brief: margins and cash flow improved sharply. The bear case: organic growth is thin.
Bull case
- Margins and cash flow improved sharply. Third-quarter adjusted operating income was $142.6 million, up from $105.9 million a year earlier, and free cash flow improved by $151 million year over year (company news and IBTimes, 4 November 2026). The adjusted EPS beat of $0.14 came from margin, not sales.
- Bookings recovery is broadening. Bruker Scientific Instruments (BSI) has had a book-to-bill ratio above 1.0 for five straight quarters, with U.S. academic and government bookings up double digits and China bookings up more than 20% in the quarter (MarketBeat call summary, 4 November 2026).
- Management guides to faster fourth-quarter growth. Bruker expects lower-mid-single-digit organic revenue growth in the fourth quarter and double-digit EPS growth in fiscal 2027, per IBTimes coverage of the call (4 November 2026).
- Brokers raised targets after the report. Leerink maintained Outperform and raised its target to $85; Citigroup maintained Neutral and raised its target to $64 (company news, 5 November 2026).
- Semiconductor exposure adds a second driver. Investing.com reported on 29 September 2026 that semiconductor-exposed businesses generate about $350 million in sales, roughly 9% to 10% of Bruker revenue.
Bear case
- Organic growth is thin. Third-quarter organic revenue rose 0.7%, down from 2.8% in the second quarter (Bruker releases, 4 November 2026 and 4 August 2026). BSI organic revenue fell 0.4% in the quarter (SEC Form 8-K summary, 4 November 2026).
- Revenue guidance was cut a second time. The reported range fell to $3.520–$3.560 billion after the August cut to $3.540–$3.570 billion. ChartMill noted the new range sits below consensus (via IBTimes, 4 November 2026).
- Reported earnings keep diverging from adjusted. A $174.5 million goodwill impairment produced a third-quarter GAAP (generally accepted accounting principles) loss of $0.81 per share against $0.56 adjusted (SEC Form 8-K, 4 November 2026). The second quarter carried a $134.9 million impairment.
- Softer bookings in parts of the book. Some analysts noted that bookings growth slowed from the prior quarter and that European pharma orders softened (Earnings Whispers, 4 November 2026).
- Financing overhang remains. A universal registration statement has been effective since 12 June 2026, and the $600 million 6.375% mandatory convertible preferred ranks ahead of common shares.
Price setup
The adjusted close on 10 November 2026 was $62.24, with the 14-day relative strength index (RSI) at 54.0, a neutral reading. The shares are up 7.5% over three months. The 52-week high in adjusted daily closes is $66.54, up from $64.75 on 28 October 2026, so the shares set a new high after the report and have since given back 6.5%.
Analyst targets bracket the price: JPMorgan's Neutral target is $60 (14 October 2026), TD Cowen's Hold target is $62 (13 October 2026), Citigroup's Neutral target is $64 and Leerink's Outperform target is $85 (both 5 November 2026). The current close sits near the middle of the neutral-rated targets.
Crowding evidence is modest. No earnings date falls inside the next 30 days, and no insider-selling data point is available. Share issuance risk rests on the effective registration statement, with no common-stock pricing reported.
Catalysts ahead
- Early February 2027 (est.): Fourth-quarter 2026 report with formal 2027 guidance. Tests management's lower-mid-single-digit fourth-quarter organic growth target and the double-digit fiscal 2027 EPS growth outlook.
What would change the view
A daily close below $56, which would erase the advance that followed the 4 November 2026 third-quarter report; a fourth-quarter organic revenue decline or a new goodwill impairment would also break the case.
The risks this note tracks, each with what would confirm it:
- Organic growth stays near zero despite stronger bookings. Confirmed by: fourth-quarter organic revenue below the lower-mid-single-digit range management set on 4 November 2026.
- Further acquisition-related write-downs continue. Confirmed by: a new goodwill or intangible impairment after the $174.5M charge reported 4 November 2026.
- Common-equity issuance dilutes shareholders. Confirmed by: a prospectus supplement pricing common stock under the 12 June 2026 registration.
- European pharma orders weaken further. Confirmed by: bookings growth slowing again at the February 2027 report, as some analysts flagged for the third quarter.
What it trades with
Bruker's life-science instrument demand follows U.S. academic and government funding, China orders and pharma capital spending, all named in the third-quarter commentary. Semiconductor-process businesses, about 9% to 10% of revenue per Investing.com (29 September 2026), tie part of the business to chipmaker spending. German manufacturing makes the EUR/USD exchange rate a swing factor between reported and organic revenue, which is why the 4 November 2026 sales cut was currency-driven.
The evidence, claim by claim (7)
- Q3 2026 revenue was $874.0M, up 1.6% reported and 0.7% organic, against a $868.8M estimate; adjusted EPS was $0.56 against a $0.42 estimate. Bruker Q3 2026 results release / SEC Form 8-K · as of
- Adjusted operating margin was 16.3% versus 12.3% a year earlier; free cash flow was $96.7M versus $(54.1)M. Bruker Q3 2026 results release · as of
- FY2026 reported revenue guidance was lowered to $3.520-$3.560B from $3.540-$3.570B; adjusted EPS guidance of $2.10-$2.15 was affirmed. Bruker Q3 2026 results release · as of
- A $174.5M goodwill impairment produced a Q3 GAAP loss of $0.81 per share. SEC Form 8-K, Exhibit 99.1 · as of
- BSI book-to-bill has been above 1.0 for five straight quarters; U.S. academic and government bookings grew double digits and China bookings rose more than 20% in Q3. MarketBeat earnings call summary · as of
- Leerink maintained Outperform and raised its target to $85; Citigroup maintained Neutral and raised its target to $64. Company news headlines · as of
- Adjusted daily close was $62.24 against a 52-week high of $66.54; RSI(14) was 54.0. Adjusted daily closes · as of
Sources
- BRUKER CORP - Form 8-K - FY2026 · sec.gov
- Bruker Reports Third Quarter 2026 Financial Results · finviz.com
- MarketBeat ·
- Bruker Stock Surges as Sharp Margin Expansion and Big Earnings Beat Overshadow Goodwill Charge and Slow Sales · ibtimes.com.au ·
- Bruker (BRKR) Q3 2026: Margin Surge Masks a Steep Goodwill Charge · 247wallst.com